EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Cofoe Medical Technology Co.,Ltd. (1187) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Cofoe Medical Technology Co.,Ltd. HK$44.85, price HK$28.70, upside +56.3%, quality 74 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · HK

CM Broad data Sep 27, 2026

Cofoe Medical Technology Co.,Ltd.

1187 · HK

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value HK$44.85 · Strongly undervalued (+56.3%)
✓Quality 74/100
✓Healthy Growth (revenue 3y +4.4 %/yr)
✓Solidly profitable · 10.6% net margin (TTM)
✓Low debt · generates free cash flow
✓Ranks above peers (14/14)
!Narrow moat 43/100
Watch Cofoe Medical Technology Co.,Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$39.00 HK$26.32 Fair Value HK$44.85 May 2026 Sep 2026

White line = price, green steps = our fair value per fiscal year. As of Sep 27, 2026.

How to read this chart

5‑month range HK$26.32 – HK$39.00 · fair‑value band HK$34.28 – HK$54.25 · the HK$28.70 price screens below the HK$44.85 fair value. As of Sep 27, 2026.

Follow Cofoe Medical Technology Co. in your weekly email

Every Wednesday you see whether Cofoe Medical Technology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cofoe Medical Technology Co., Ltd. engages in the research and development, production, sales, and service of home care medical devices in China. The company offers medical and wellness products for various types of diseases treatment, damage therapy, daily health maintenance, and life quality improvement.

Show more

Cofoe Medical Technology Co., Ltd. engages in the research and development, production, sales, and service of home care medical devices in China. The company offers medical and wellness products for various types of diseases treatment, damage therapy, daily health maintenance, and life quality improvement. It also offers rehabilitation aids products, such as hearing aids, electric wheelchair, and orthopedic/posture correction products; medical care products, such as dressing products and ostomy care products; health monitoring products for monitoring human physiological parameters including metabolic disease testing product and thermometers; respiratory support products including non-invasive ventilators and nebulizers; and TCM therapy and other products, such as physiotherapy devices. Additionally, the company offers logistics and warehousing services to third party medical product companies and on-line storemanagement services. Further, the company manufactures its products through the Original Design Model, through which, it collaborates with customers to develop designs of products itmanufactures; and the original equipment manufacturing model, through which its customers provide their designs and it manufactures. The company sells its products through both offline and online channels comprising direct sales primarily via self-owned and online stores, sales to third party pharmacy chain operators, sales to offline and online distributors, and through e-commerce platforms. It sells its products through its brands Cofoe, JOYOR HearingCare, Jerry Medical, Huazhou, and babaka. The company was formerly known as Hunan Cofoe Medical Technology Development Co., Ltd. and changed its name to Cofoe Medical Technology Co.,Ltd. in December 2026. Cofoe Medical Technology Co., Ltd. was founded in 2005 and is headquartered in Changsha, China.

Stock analysis

Cofoe Medical Technology Co.,Ltd. (1187) currently trades at HK$28.70, while our model-based Fair Value estimate is HK$44.85, implying the stock looks roughly 36.0% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of HK$47.46 per share, and 18 of the 24 models we run sit above the HK$28.70 price.

Bear case: the Earnings-Based group reads lowest at HK$13.55, and 6 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: HK$34.28 (bear) to HK$54.25 (bull), the price of HK$28.70 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Cofoe Medical Technology Co.,Ltd. reported revenue of 3.4B CNY in FY2025 versus 3.0B CNY in FY2022, a compound +4.4%/yr. Reported net income was 372M CNY in FY2025, compounding +7.2%/yr from FY2022.

Key figures

Market cap HK$7.0B (≈ $887M) · P/E ratio 13.6 · P/S ratio 1.49 · Dividend yield 5.3% · Net margin 11.0% · Return on equity 8.0% · Return on assets (EBIT) 5.3% · Operating margin 13.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 56%, 1187 screens cheaper than that median.

Fair Value models

Bear HK$34.28 Fair Value HK$44.85 Bull HK$54.25
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF HK$35.11 HK$47.46 HK$63.89 78
Growth DCF HK$35.29 HK$46.03 HK$59.43 77
Owner Earnings HK$27.75 HK$36.84 HK$48.93 74
All 24 models by family
DCF Models
FCF DCF HK$35.11 HK$47.46 HK$63.89 78
Owner Earnings HK$27.75 HK$36.84 HK$48.93 74
5Y Revenue Exit HK$29.86 HK$41.07 HK$55.07 70
5Y EBITDA Exit HK$36.47 HK$53.41 HK$72.96 72
5Y P/E Exit HK$36.61 HK$53.66 HK$71.41 68
10Y Revenue Exit HK$31.21 HK$41.35 HK$54.47 65
10Y EBITDA Exit HK$35.58 HK$49.17 HK$66.92 66
10Y P/E Exit HK$35.66 HK$49.33 HK$65.84 62
Earnings-Based
Graham-Dodd HK$14.15 HK$43.79 HK$58.20 62
Lynch FV HK$9.48 HK$13.55 HK$17.61 58
PEG = 1.0 HK$9.48 HK$13.55 HK$17.61 55
EPV HK$21.26 HK$23.17 HK$24.76 71
Multiples
P/E Multiple HK$34.34 HK$45.78 HK$57.23 63
P/S Multiple HK$26.53 HK$35.38 HK$44.22 58
P/B Multiple HK$26.53 HK$35.38 HK$44.22 55
EV/EBIT HK$35.50 HK$44.92 HK$54.33 66
EV/EBITDA HK$41.34 HK$52.69 HK$64.05 67
EV/Revenue HK$27.42 HK$36.06 HK$44.70 54
Asset-Based
NCAV (Graham) HK$13.63 HK$18.26 HK$27.25 54
Growth DCF
Growth DCF HK$35.29 HK$46.03 HK$59.43 77
Rev-Margin DCF HK$29.86 HK$41.34 HK$54.60 70
Economic Profit
Residual Income HK$21.27 HK$21.98 HK$24.06 73
ROIC Compounder HK$21.26 HK$23.17 HK$24.76 69
Growth Earnings
Growth-Adj P/E HK$28.20 HK$40.28 HK$52.37 65

Open the full fair value analysis →

Notify me when 1187 reaches fair value

Put 1187 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 74/100

Of which business quality 73 · Market factors (momentum, volatility) 35

Profitability 43
Margins and returns on capital today
Quality Growth 64
Are margins and returns improving?
Cashflow 75
Earnings quality: real cash, not paper profit
Fin. Strength 93
Balance sheet, leverage, solvency risk
Investment 92
Disciplined investing over empire-building
Low Volatility 57
Calm price path (market factor)
Momentum 39
Price trend over the last 3–12 months (market factor)
52W Momentum 4
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 72/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+13.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+15.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+10.1%
Dividend (yield on the price)5.3%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 12%

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−3.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+16.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −5.4% a year for the price and +14.3% for the forecasts.
Forecast 2026 (sales)+18.8%
Forecast 2027 (sales)+18.8%
Projected 2028 (sales)+16.7%
Projected 2029 (sales)+14.6%
Projected 2030 (sales)+12.5%

Watch 1187, get fair value alerts →

Compare Cofoe Medical Technology Co.,Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 357 stocks

Beats the industry median on 14/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 74 · Top 25%
Fair Value upside +53.5% · Top 25%
Profitability
Return on equity (TTM) 8.0% · Above median
Return on assets 3.3% · Above median
Net margin (TTM) 10.6% · Above median
Operating margin (TTM) 13.3% · Above median
Growth and dividend
Revenue growth 37.2% · Top 25%
Dividend yield (TTM) 5.3% · Top 25%
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 13.6× · Cheapest 25%
P/B 1.22× · Cheaper than median
P/S (TTM) 1.62× · Cheaper than median
P/FCF 11.5× · Cheapest 25%
EV/EBITDA 9.9× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 5
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)32 · sector 8
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)100 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $101.29 $74.79 −26%
Medtronic plc MDT $88.64 $65.61 −26%
Stryker Corporation SYK $272.36 $299.60 +10%
Boston Scientific Corporation BSX $43.92 $48.31 +10%
Edwards Lifesciences Corporation EW $86.29 $81.94 −5%
Siemens Healthineers AG SHL €37.79 €35.19 −7%
DexCom, Inc DXCM $86.68 $95.35 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cofoe Medical Technology Co.,Ltd. · Fair Value
HK$44.85 +36%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Cofoe Medical Technology Co.,Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/1187

Frequently asked questions

Is Cofoe Medical Technology Co.,Ltd. (1187) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$44.85 versus a price of HK$28.70, about +56% upside (undervalued).
What is the fair value of 1187?
Our model-based fair value for Cofoe Medical Technology Co.,Ltd. is HK$44.85 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$28.70.
What is the quality score of 1187?
Cofoe Medical Technology Co.,Ltd. has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cofoe Medical Technology Co.,Ltd. (1187)?
Our model-based price target is the fair value of HK$44.85 (as of Sep 27, 2026) from 24 valuation models. Cautious scenario HK$34.28, optimistic scenario HK$54.25. It is a calculation from audited fundamentals, not an analyst target.
What is the Cofoe Medical Technology Co.,Ltd. stock forecast for 2026?
Our models put fair value at HK$44.85, about +56% upside versus a price of HK$28.70 (undervalued). Cautious scenario HK$34.28, optimistic scenario HK$54.25. The calculation is refreshed regularly with new filings.
What is the revenue of Cofoe Medical Technology Co.,Ltd. (1187)?
Cofoe Medical Technology Co.,Ltd. reported trailing-twelve-month revenue of about 3.7B CNY (latest available figure, as of Sep 27, 2026).
Does Cofoe Medical Technology Co.,Ltd. pay a dividend?
Cofoe Medical Technology Co.,Ltd. currently shows a dividend yield of about 5.34% relative to its recent price (as of Sep 27, 2026).
What growth is priced into Cofoe Medical Technology Co.,Ltd. (1187)?
For today's price to be fair in a discounted-cash-flow model, Cofoe Medical Technology Co.,Ltd. would have to grow free cash flow by -3.8 % per year for five years (discount rate 10.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +4.4 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of 1187 use?
Our models discount Cofoe Medical Technology Co.,Ltd. at 10.8 %: a base by market capitalisation (small), damped by beta 0.66, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Cofoe Medical Technology Co.,Ltd. that is -3.8 % per year a year over ten years, using the same discount rate (10.8 %) and the same formula as our fair value.
How much growth has Cofoe Medical Technology Co.,Ltd. (1187) delivered so far?
Over the past 3 years revenue at Cofoe Medical Technology Co.,Ltd. grew +4.4 % a year. The price currently implies -3.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Cofoe Medical Technology Co.,Ltd. (1187) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Cofoe Medical Technology Co.,Ltd. (-3.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Cofoe Medical Technology Co.,Ltd. (1187)?
The free-cash-flow yield on the price is 10.10 %: that much free cash flow Cofoe Medical Technology Co.,Ltd. produces per unit of market value. When it exceeds the discount rate of our models (10.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Cofoe Medical Technology Co.,Ltd. (1187)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cofoe Medical Technology Co.,Ltd. it is HK$44.85 per share (as of Sep 27, 2026), against a price of HK$28.70. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Cofoe Medical Technology Co.,Ltd. stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 1187 trades below its calculated fair value: price HK$28.70, fair value HK$44.85, a gap of about +56% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1187?
No. The price is what the market pays today (HK$28.70); the fair value is what the company's own numbers justify (HK$44.85). For Cofoe Medical Technology Co.,Ltd. the two are HK$16.15 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cofoe Medical Technology Co.,Ltd. worth?
The market values Cofoe Medical Technology Co.,Ltd. at about HK$7.0B (market capitalisation, as of Sep 27, 2026). Per share that is HK$28.70; our models calculate a fair value of HK$44.85 per share.
What do the bullish and bearish scenarios say about 1187?
Our models span a range for Cofoe Medical Technology Co.,Ltd.: cautious scenario HK$34.28, base HK$44.85, optimistic HK$54.25 per share (as of Sep 27, 2026, price HK$28.70). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1187?
Cofoe Medical Technology Co.,Ltd. trades at a price-to-earnings ratio of 13.6 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$44.85 is built from several models across several years. Other multiples: P/B 1.2, P/S 1.6, EV/EBITDA 9.9.
How solid is the balance sheet of Cofoe Medical Technology Co.,Ltd. (1187)?
Balance-sheet figures for Cofoe Medical Technology Co.,Ltd. (as of Sep 27, 2026): return on equity 8.0%, debt of 0.03 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
Which stocks are comparable to Cofoe Medical Technology Co.,Ltd.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cofoe Medical Technology Co.,Ltd. stock attractive at the current price?
The data as of Sep 27, 2026: price HK$28.70, calculated fair value HK$44.85 (+56%), Quality Score 74/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1187 calculated?
We run Cofoe Medical Technology Co.,Ltd. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$44.85, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Cofoe Medical Technology Co.,Ltd. currently trades 36 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cofoe Medical Technology Co.,Ltd. (1187)?
The closing price on Sep 30, 2026 was HK$28.70. Our model-based fair value is HK$44.85, about +56% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cofoe Medical Technology Co.,Ltd. right now?
The rarer combination: high quality (74/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (HK$34.28). The market is more pessimistic than our downside scenario.

Key figures of Cofoe Medical Technology Co.,Ltd.

How large is the market capitalisation of Cofoe Medical Technology Co.,Ltd. (1187)?
The market capitalisation of Cofoe Medical Technology Co.,Ltd. is HK$7.0B (≈ $887M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cofoe Medical Technology Co.,Ltd. (1187)?
The price-to-sales ratio of Cofoe Medical Technology Co.,Ltd. is 1.49 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Cofoe Medical Technology Co.,Ltd. (1187)?
The dividend yield of Cofoe Medical Technology Co.,Ltd. is 5.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Cofoe Medical Technology Co.,Ltd. (1187)?
The net margin of Cofoe Medical Technology Co.,Ltd. is 11.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cofoe Medical Technology Co.,Ltd. (1187)?
The return on equity (ROE) of Cofoe Medical Technology Co.,Ltd. is 8.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cofoe Medical Technology Co.,Ltd. (1187)?
On an EBIT basis the return on assets of Cofoe Medical Technology Co.,Ltd. is 5.3% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cofoe Medical Technology Co.,Ltd. (1187)?
The operating margin of Cofoe Medical Technology Co.,Ltd. is 13.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cofoe Medical Technology Co.,Ltd. (1187)?
Revenue at Cofoe Medical Technology Co.,Ltd. is growing +37.2% versus a year earlier (3y avg +4.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cofoe Medical Technology Co.,Ltd. (1187)?
Earnings per share at Cofoe Medical Technology Co.,Ltd. are growing +15.9% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch Cofoe Medical Technology Co.,Ltd. in the live analysis

One click puts Cofoe Medical Technology Co.,Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.